• 1
    Franco EL,Cuzick J,Hildesheim A,de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006; 24( suppl 3): S171S177.
  • 2
    Bosch FX. Preface. Vaccine. 2006; 24S3: vvi.
  • 3
    Richart RM,Barron BA. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol. 1969; 105: 386393.
  • 4
    Stoler MH,Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 15001505.
  • 5
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813819.
  • 6
    Moscicki AB,Schiffman M,Kjaer S,Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006; 24( suppl 3): S42S51.
  • 7
    Castle PE,Schiffman M,Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005; 191: 18081816.
  • 8
    Plummer M,Schiffman M,Castle PE,Maucort-Boulch D,Wheeler CM,for the ASCUS-LSIL Triage Study (ALTS) Group. Toward defining HPV persistence: a two-year prospective study of individual types of cervical human papillomavirus infection among women with ASCUS or LSIL cytology. J Infect Dis. In press.
  • 9
    Cogliano V,Baan R,Straif K,Grosse Y,Secretan B,El Ghissassi F,WHO International Agency for Research on Cancer.Carcinogenicity of human papillomaviruses.Lancet Oncol. 2005; 6: 204.
  • 10
    Khan MJ,Castle PE,Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 10721079.
  • 11
    Cox JT,Schiffman M,Solomon D, ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003; 188: 14061412.
  • 12
    Kovacic MB,Castle PE,Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006; 66: 1011210119.
  • 13
    Swan DC,Tucker RA,Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999; 37: 10301034.
  • 14
    Sherman ME,Wang SS,Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003; 12: 10381044.
  • 15
    Snijders PJ,van den Brule AJ,Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003; 201: 16.
  • 16
    Gravitt P,Butsch Kovacic M,Herrero R, et al. HPV viral load of most genotypes is associated with prevalent diagnoses of high-grade CIN, but only HPV16 load predicts incident diagnoses. Int J Cancer. In press.
  • 17
    Davey DD,Neal MH,Wilbur DC,Colgan TJ,Styer PE,Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004; 128: 12241229.
  • 18
    Bosch FX,de Sanjose S. Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;( 31): 313.
  • 19
    Solomon D. Chapter 14: role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr. 2003;( 31): 97101.
  • 20
    Schiffman M,Castle PE. When to test women for human papillomavirus. BMJ. 2006; 332: 6162.
  • 21
    Saslow D,Runowicz CD,Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. J Low Genit Tract Dis. 2003; 7: 6786.
  • 22
    Wright TCJr,Cox JT,Massad LS,Twiggs LB,Wilkinson EJ, ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 21202129.
  • 23
    Wright TCJr,Cox JT,Massad LS,Carlson J,Twiggs LB,Wilkinson EJ, for the American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2003; 189: 295304.
  • 24
    Koliopoulos G,Arbyn M,Martin-Hirsch P,Kyrgiou M,Prendiville W,Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007; 104: 232246.
  • 25
    Villa LL,Costa RL,Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271278.
  • 26
    Mao C,Koutsky LA,Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107: 1827. Erratum in: Obstet Gynecol. 2006; 107: 1425.
  • 27
    Harper DM,Franco EL,Wheeler CM, et al.,HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 12471255.
  • 28
    Koutsky LA,Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine. 2006; 24( suppl 3): S114S121.
  • 29
    Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med. 2006; 355: 23892391.
  • 30
    [No authors listed] Flogging Gardasil. Nat Biotechnol. 2007; 25: 261.
  • 31
    Jeronimo J,Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol. 2006; 195: 349353.
  • 32
    Jeronimo J,Massad LS,Schiffman M, for the NIH-ASCCP Research Group. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. In press.
  • 33
    Castle PE,Solomon D,Schiffman M,Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005; 97: 10661071.
  • 34
    Saslow D,Castle PE,Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 728.
  • 35
    Kulasingam SL,Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781789.
  • 36
    Eltoum IA,Roberson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer (Cancer Cytopathology). 2007; 111: 3440.
  • 37
    Kjaer S,Hogdall E,Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006; 66: 1063010636.
  • 38
    Schiffman M,Herrero R,Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337: 7684.
  • 39
    Bulkmans NW,Berkhof J,Bulk S, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer. 2007 [Epub ahead of print].
  • 40
    Stoler MH,Castle PE,Solomon D,Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 13.
  • 41
    Wright TCJr,Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003; 348: 489490.
  • 42
    Schiffman M,Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005; 353: 21012104.
  • 43
    Kinney WK,Manos MM,Hurley LB,Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998; 91: 973976.
  • 44
    Munoz N,Bosch FX,Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 111: 278285.